On Feb. 4, 2026, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic® (semaglutide) oral tablets at doses of 1.5 mg, 4 mg and 9 mg for use in adults with type 2 diabetes. When combined with proper diet and exercise, Ozempic tablets are indicated to improve glycemic control and reduce the risk of major adverse cardiovascular events in adults.
To simplify the recognition of oral and injectable semaglutide‑based treatment options, the FDA also approved Ozempic as the proprietary name, replacing the use of Rybelsus.®
Following a bioequivalence study and clinical trial for oral semaglutide, it was found that the lower-milligram doses of the Ozempic oral formulation offer similar efficacy and safety as compared to the previously known oral semaglutide Rybelsus (3 mg, 7 mg and 14 mg doses).
The Ozempic tablet is expected to launch in the U.S. in the second quarter of 2026. Patients currently prescribed Rybelsus should continue therapy until additional transition guidance is provided.
Novo Nordisk has also submitted 25 mg Ozempic tablets for use in adults with type 2 diabetes, with an FDA decision expected by the end of 2026.
MyMatrixx by Evernorth Actions
MyMatrixx by Evernorth is dedicated to helping our clients monitor and manage the cost and utilization of injury-related medications and the medications that may aid in an injured worker’s overall recovery. We will continue to evaluate workers' compensation claim-related uses for semaglutides to determine if they are an appropriate addition to our formularies. If you have any questions, please reach out to your MyMatrixx account team.